Innovent Biologics, Inc. (FRA:6IB)
Germany · Delayed Price · Currency is EUR | Market Cap | 14.68B +55.1% |
| Revenue (ttm) | 1.59B +38.4% |
| Net Income | 99.07M |
| EPS | 0.06 |
| Shares Out | n/a |
| PE Ratio | 148.22 |
| Forward PE | 38.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 8.28 |
| Previous Close | 8.62 |
| Day's Range | 8.28 - 8.49 |
| 52-Week Range | 7.00 - 11.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimum... [Read more]
News
Innovent Biologics announces results from PoC study of IBI363
Innovent Biologics (IVBXF) announced the preliminary results from a PoC clinical study of its global first-in-class PD-1/IL-2alpha-bias bispecific fusion protein IBI363 plus chemotherapy in the first-...
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression . The 3→ 1.5 mg/kg do...
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinic...
Pfizer (PFE) Enters $10.5B Oncology Partnership with Innovent
Pfizer (PFE) Enters $10.5B Oncology Partnership with Innovent
Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging
Pfizer's $10.5 Billion Oncology Bet Sends Innovent Shares Surging
Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal
Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal
Pfizer (PFE) Partners with Innovent Biologics in $10.5B Oncology Deal
Pfizer (PFE) Partners with Innovent Biologics in $10.5B Oncology Deal
Pfizer Enters Deal With Innovent Biologics To Co-Develop Oncology Medicines
(RTTNews) - Pfizer Inc. (PFE), a biopharmaceutical company, announced on Friday that it has entered into a strategic global licensing and collaborative agreement with Innovent Biologics to research an...
China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials
China’s Innovent Biologics has signed a global collaboration with pharmaceutical giant Pfizer worth up to US$10.5 billion to jointly develop 12 cancer treatment programmes. The Hong Kong-listed drug m...
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in th...
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 ear...
Pfizer enters into global strategic collaboration with Innovent Biologics
Pfizer (PFE) and Innovent Biologics (IVBXF) announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new brea...
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable S
SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma
(RTTNews) - HUTCHMED (HCM) and Innovent Biologics, Inc (HKEX:1801) said the China National Medical Products Administration (NMPA) has approved the combination of ELUNATE (fruquintinib) and TYVYT (sint...
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics...
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
SAN FRANCISCO and SUZHOU, China, May 18, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions
SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
SAN FRANCISCO and SUZHOU, China, May 10, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes...
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
SAN FRANCISCO and SUZHOU, China, April 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
SAN FRANCISCO and SUZHOU, China, April 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to fari...
Innovent Announces 2025 Annual Results and Business Updates
From China Leadership to Global Premier: Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent ...
Innovent Biologics Earnings release: H2 2025
Innovent Biologics released its H2 2025 earnings on March 26, 2026, summarizing the period's financial results.
Innovent Biologics Slides: H2 2025
Innovent Biologics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 26, 2026.